Physician profile
Michael Duane Moore
NPI 1831184456
$26,544.79
in general payments reported to CMS, 2019-2025
25 companies · $1,356 in 2025
The $1,356 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $344 · 2020: $418 · 2021: $1,136 · 2022: $656 · 2023: $11K · 2024: $12K · 2025: $1,356.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $20K · Food and Beverage: $2,851 · Travel and Lodging: $1,140.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $20,000.00 |
| Food and Beverage | $2,851.21 |
| Travel and Lodging | $1,139.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Angiodynamics, INC. | $20,000.00 | 2023-2024 | Auryon Laser System 100-120 Vac |
| Medtronic, INC. | $2,020.43 | 2023-2024 | Micra, Azure Xt Dr Mri Surescan, Cobalt Dr Mri Surescan |
| Boston Scientific Corporation | $1,415.56 | 2019-2025 | Lux-Dx Insertable Cardiac Monitor, Versacross Connect Laac Access Solution, Acuity Steerable |
| Edwards Lifesciences Corporation | $915.36 | 2021-2022 | |
| Abiomed | $830.30 | 2024-2025 | Impella |
| Astellas Pharma US INC | $215.52 | 2020 | |
| Bolton Medical INC | $167.63 | 2025 | Relay Thoracic Stent-Graft With Plus Delivery System |
| Shockwave Medical, INC | $162.26 | 2021 | |
| Novartis Pharmaceuticals Corporation | $140.39 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $136.48 | 2021-2025 | Lifevest |
| Kestra Medical Technology Services, INC. | $87.10 | 2025 | Assure Wcd |
| Janssen Pharmaceuticals, INC | $78.32 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.70 | 2019-2023 | Jardiance |
| Abbott Laboratories | $67.51 | 2025 | Cardiomems |
| E.R. Squibb & Sons, L.L.C. | $61.49 | 2019-2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $32.07 | 2020-2021 | |
| Kowa Pharmaceuticals America, INC. | $31.43 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $29.24 | 2025 | |
| Cook Medical LLC | $20.55 | 2019 | |
| Medtronic Vascular, INC. | $16.92 | 2019 | |
| Lundbeck LLC | $13.74 | 2020 | |
| Pfizer INC. | $12.78 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $11.58 | 2021 | |
| Cardiovascular Systems INC. | $4.43 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.